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TO THE EDITOR
Transient receptor potential vanilloid
type 1 (TRPV1) is a non-selective cation
channel widely expressed in skin tis-
sues, including keratinocytes and per-
ipheral sensory nerve fibers (C and Ad).
Activated by noxious heat, capsaicin, or
endogenous inflammatory mediators,
TRPV1 can provoke neuropeptide re-
leases and propagate neurogenic inflam-
mation, which ultimately contributes
to the development of diverse derma-
toses and pruritus (Hutter et al., 2005;
Shim et al., 2007; Imamachi et al.,
2009). Recently, we demonstrated that
a novel and potent TRPV1 antagonist,
PAC-14028 ((E)-N-((R)-1-(3,5-difluoro-
4-methanesulfonylamino-phenyl)-ethyl)-
3-(2-propyl-6-trifluoromethyl-pyridine-
3-yl)-acrylamide) can alleviate atopic
dermatitis (AD)-like symptoms through
the acceleration of skin barrier re-
covery (Yun et al., 2011). Of note,
we discovered that PAC-14028 could
also suppress scratching behavior sig-
nificantly. Severe itch symptom is a
hallmark of AD and at the same time,
the representative unmet medical need
in diverse skin diseases (Steinhoff et al.,
2006). Here, we investigated the anti-
pruritic effects of PAC-14028 and ex-
plored the mechanism underlying them
to examine the utility of a TRPV1 anta-
gonist as a novel antipruritic therapy.
AD-like symptoms were induced in
male NC/Nga mice (8-week old, twice
a week for 3 weeks) with the repeated
topical application of allergen, Derma-
tophagoides farina (Df) extract, the
major species of house dust mites, on
the shaved dorsum as previously de-
scribed (Bae et al., 2010). All animal
experiment procedures were approved
by the AmorePacific Institutional Ani-
mal Care and Use Committee. PAC-
14028, which is a potent and selec-
tive TRPV1 antagonist as determined
by resiniferatoxin-induced Ca2þ influx
assay in rat TRPV1-expressed CHO
cells (Figure 1a) and capsaicin-induced
Ca2þ influx in dorsal root ganglia
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neurons as reported in our previous
study (Yun et al., 2011), was adminis-
tered daily (30mg kg1 orally dispersed
in 0.5% Tween 80 and 1% methylcellu-
lose). Serum IgG1, a TH2 cell-associated
immunoglobulin, was significantly
increased in the Df group, whereas
serum IgG2a, a marker of TH1 immune
response (Chan et al., 2001), was
marginally insignificant (Figure 1b),
reflecting that TH2 type dermatose was
developed by multiple challenges of
Df. Consistently with the development
of AD-like symptoms, bouts of scratch-
ing increased along with larger number
of mast cells in the dermis of Df-applied
animals (Figure 1c and d). Importantly,
both the proportion and total number
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Figure 1. Effects of TRPV1 antagonist, PAC-14028, on Df-induced AD-like symptoms in NC/Nga mice. (a) Resiniferatoxin-induced Ca2þ influx in
rTRPV-expressed CHO cells. (b) Serum IgG1 and IgG2a levels measured with ELISA kits. IgG2a (BD Bioscience, Mississauga, ON, Canada), IgG1 (Bethyl
Laboratories, Montgomery, TX). (c) The granulated (black arrows) and degranulated (white arrows) mast cells in the AD-like skin lesion stained with toluidine
blue. Scale bar is 50 mm. (d) The scratching behaviors in NC/Nga mice. The number of scratches with hindpaws (for 5 hours) and forepaws (for 2 hours)
were counted using MicroAct (Neuroscience, Tokyo, Japan) and digital video camcorder, respectively. The data are presented as means±SE (N¼ 5–6).
#Significantly different from vehicle (Veh) control group (Po0.05). *Significantly different from Df group (Po0.05). AD, atopic dermatitis; Df,
Dermatophagoides farina; PAC-14028, (E)-N-((R)-1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl)-3-(2-propyl-6-trifluoromethyl-pyridine-3-yl)-acryla-
mide; TRPV1, transient receptor potential vanilloid type 1; Veh, vehicle control; 14028, PAC-14028.
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of degranulated mast cells increased
significantly in the Df-treated group.
Mast cell degranulation leads to the
release of granule-associated prurito-
genic mediators, including histamine,
serotonin, and protease-activated rece-
ptor-2 (PAR-2) activating tryptase into
skin tissue, initiating the itch symptoms
(Caughey, 2007; Shim et al., 2007; Costa
et al., 2008; Imamachi et al., 2009).
Notably, the treatment of PAC-14028
significantly attenuated the degranula-
tion of mast cells and scratching beha-
viors along with reduced IgG2a,
indicating that PAC-14028 can suppress
AD-associated pruritus and prevent the
development of TH2 type dermatoses.
TRPV1 is upregulated in the AD-skin
lesion, and the activation of TRPV1
causes the release of proinflammatory
and pruritic mediators (Steinhoff et al.,
2004; Hutter et al., 2005; Imamachi
et al., 2009). Therefore, we sought to
determine the expression and/or phos-
phorylation of TRPV1 in AD-like skin
lesions in vivo. Both TRPV1 and phos-
phorylated TRPV1 increased in the
AD-like skin lesions of the Df-treated
groups (Figure 2a), reflecting that the
activity and functionality of TRPV1 may
substantially increase in AD. The acti-
vation of TRPV1 leads to the release of
substance P and subsequently upregu-
lates neurokinin-1 receptor (Velazquez
et al., 2002; Hutter et al., 2005). In
addition to TRPV1 and phosphorylated
TRPV1, neurokinin-1 receptor expres-
sion increased substantially in the
AD-like lesion (Figure 2a), indicating
that TRPV1 was activated and sub-
stance P was released in AD-like lesion.
In contrast, although PAC-14028 treat-
ment did not affect TRPV1 expression
and phosphorylation, it significantly
reduced the expression of neurokinin-
1 receptor, reflecting that PAC-14028
suppressed the release of substance P
through the blockade of TRPV1 activa-
tion. Substance P can contribute to the
development of neurogenic inflamma-
tion and pruritus, and neurokinin-1
receptor antagonists could suppress
scratching behaviors (Ohmura et al.,
2004; Yamaoka and Kawana, 2007),
suggesting that antipruritic effect of
TRPV1 antagonist in AD may be ex-
plained, at least in part, by the suppres-
sion of substance P release.
To further explore the mechanism
underlying the antipruritic effect of
PAC-14028, the effects on the scratch-
ing responses evoked by diverse prur-
itogens were examined. The scratching
behaviors induced by resiniferatoxin,
a TRPV1 agonist, were significantly
inhibited by PAC-14028 treatment in
a dose-dependent manner, confirming
the efficacy of PAC-14028 against
TRPV1-mediated pruritus. Interestingly,
the scratching bouts evoked by PAR-
2-activating peptide, SLIGRL-NH2
(Shimada et al., 2006), were also
significantly attenuated by PAC-14028
(Figure 2b). This antipruritic effect of
PAC-14028 on PAR-2-mediated pruri-
tus might support the close relation-
ship between PAR-2 activation and
TRPV1 sensitization, which has been
addressed by several studies in diverse
inflammation, pain states, and espe-
cially pruritus (Costa et al., 2008).
Meanwhile, the scratching behaviors
induced by mast cell degranulator, com-
pound 48/80, and the representative
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Figure 2. Effects of TRPV1 antagonist, PAC-14028, on the expression of TRPV1, pTRPV1, and NK-1R, and scratching behaviors induced by diverse
pruritogens. (a) The levels of TRPV1, pTRPV1, and NK-1R in the atopic dermatitis-like skin lesion. (b) Scratching behaviors induced by intradermal injection of
diverse pruritogens in male ICR mice. PAC-14028 was administered orally at 1 hour before the pruritogen injection. For c48/80, PAC-14028 was pretreated once
daily for 3 days. Immediately after the injection of pruritogens, scratching behaviors with hindpaws were quantified for 40minutes. The data are presented as
means±SE (N¼ 4–10). #Significantly different from vehicle control group (Po0.05). *Significantly different from respective pruritogen group (Po0.05).
Histamine, 300 nmol 50ml1; serotonin, 300 nmol 50 ml1; and U-46619, 10 nmol 50 ml1. c48/80, compound 48/80 (100mg 50 ml1); Df, Dermatophagoides
farina; NK-1R, neurokinin-1 receptor; PAC-14028, (E)-N-((R)-1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl)-3-(2-propyl-6-trifluoromethyl-pyridine-3-
yl)-acrylamide; pTRPV1, phosphorylated transient receptor potential vanilloid type 1; RTX, resiniferatoxin (10 ng 50 ml1); SLIGRL, SLIGRL-NH2 (50 mg 50ml
1);
Veh, vehicle control; 14028, PAC-14028.
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granule-associated pruritogenic media-
tor from mast cells, histamine, were
markedly inhibited by PAC-14028,
whereas those by serotonin or throm-
boxane analog, U-46619, were not
affected. Partial attenuation of hista-
mine-mediated itch response might re-
flect the partial agonistic effect of
histamine on TRPV1 activation (Shim
et al., 2007), and the lack of antipruritic
efficacy on the scratching behaviors
evoked by serotonin or U-46619 was
anticipated as these pruritogens work
through G-protein-coupled receptors,
including 5-HT receptors and TP recep-
tor (Andoh et al., 2007; Imamachi et al.,
2009), that have little cross talk with
TRPV1-mediated pathways. Partial inhi-
bition of PAC-14028 on compound 48/
80-evoked itch may be explained by the
presence of TRPV1-independent itch
signals from serotonin or other prurito-
genic mediators in mast cell granules,
despite histamine- and tryptase-mediated
(PAR-2 mediated) itch responses could
be suppressed by TRPV1 blockade.
In conclusion, we found that TRPV1
antagonist, PAC-14028, can suppress
scratching behaviors associated with
AD-like symptoms through the inhibition
of TRPV1 activation, of which expression
and phosphorylation increase in AD-like
skin lesion. Particularly, experiments
with diverse pruritogens revealed that
PAC-14028 could manifest antipruritic
effects on TRPV1-, PAR-2-, and hista-
mine-mediated scratching behaviors.
Considering the frequent failure of
conventional antipruritic therapy (i.e.,
antihistamines) in the management of
severe itch symptoms, we believe that
TRPV1 antagonists can be a novel anti-
pruritic therapy that might satisfy the
unmet medical need.
CONFLICT OF INTEREST
PAC-14028 is the patented compound of Amore
Pacific Corporation (Patent PCT/KR07/003592:
novel compounds, isomer thereof, or pharmaceu-
tically acceptable salts thereof as vanilloid recep-
tor antagonist, and pharmaceutical compositions
containing the same).
ACKNOWLEDGMENTS
This work was supported by a grant from the
Ministry of Knowledge Economy (Bio-Star,
10031636).
Jun-Won Yun1, Jung A Seo1, Won-Hee
Jang1, Hyun Ju Koh1, Il-Hong Bae1,
Young-Ho Park1 and Kyung-Min Lim1
1AmorePacific Corporation R&D Center,
Medical Beauty Research Institute,
Gyeonggi-do, Republic of Korea
E-mail: kimlim@amorepacific.com
REFERENCES
Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T
et al. (2007) Thromboxane A2 induces itch-
associated responses through TP receptors in
the skin in mice. J Invest Dermatol 127:2042–7
Bae IH, Yun JW, Seo JA et al. (2010) Immunohis-
tological comparison of cutaneous pathology
of three representative murine atopic derma-
titis models. J Dermatol Sci 59:57–60
Caughey GH (2007) Mast cell tryptases and
chymases in inflammation and host defense.
Immunol Rev 217:141–54
Chan LS, Robinson N, Xu L (2001) Expression of
interleukin-4 in the epidermis of transgenic mice
results in a pruritic inflammatory skin disease:
an experimental animal model to study atopic
dermatitis. J Invest Dermatol 117:977–83
Costa R, Marotta DM, Manjavachi MN et al. (2008)
Evidence for the role of neurogenic inflammation
components in trypsin-elicited scratching beha-
viour in mice. Br J Pharmacol 154:1094–103
Hutter MM, Wick EC, Day AL et al. (2005)
Transient receptor potential vanilloid (TRPV-1)
promotes neurogenic inflammation in the
pancreas via activation of the neurokinin-1
receptor (NK-1R). Pancreas 30:260–5
Imamachi N, Park GH, Lee H et al. (2009) TRPV1-
expressing primary afferents generate behavioral
responses to pruritogens via multiple mecha-
nisms. Proc Natl Acad Sci USA 106:11330–5
Ohmura T, Hayashi T, Satoh Y et al. (2004)
Involvement of substance P in scratching
behaviour in an atopic dermatitis model.
Eur J Pharmacol 491:191–4
Shim WS, Tak MH, Lee MH et al. (2007) TRPV1
mediates histamine-induced itching via the
activation of phospholipase A2 and 12-
lipoxygenase. J Neurosci 27:2331–7
Shimada SG, Shimada KA, Collins JG (2006)
Scratching behavior in mice induced by
the proteinase-activated receptor-2 agonist,
SLIGRL-NH2. Eur J Pharmacol 530:281–3
Steinhoff M, Bienenstock J, Schmelz M et al.
(2006) Neurophysiological, neuroimmunolo-
gical, and neuroendocrine basis of pruritus.
J Invest Dermatol 126:1705–18
Steinhoff M, Griffiths CEM, Church MK et al.
(2004) Inflammation. In: Rook’s Textbook of
Dermatology (Burns T, Breathnach S, Cox N,
Griffiths C, eds). Oxford: Blackwell Publish-
ing, 251–318
Velazquez RA, McCarson KE, Cai Y et al. (2002)
Upregulation of neurokinin-1 receptor expression
in rat spinal cord by an N-terminal metabolite of
substance P. Eur J Neurosci 16:229–41
Yamaoka J, Kawana S (2007) Rapid changes in
substance P signaling and neutral endopepti-
dase induced by skin-scratching stimulation
in mice. J Dermatol Sci 48:123–32
Yun J-W, Seo JA, Jeong YS et al. (2011) TRPV1
antagonist can suppress the atopic dermatitis-
like symptoms by accelerating skin barrier
recovery. J Dermatol Sci 62:8–15
Global Analysis of BRAFV600E Target Genes in Human
Melanocytes Identifies Matrix Metalloproteinase-1 as a
Critical Mediator of Melanoma Growth
Journal of Investigative Dermatology (2011) 131, 1579–1583; doi:10.1038/jid.2011.65; published online 31 March 2011
TO THE EDITOR
BRAF kinase has been found to be
mutationally activated in up to 70% of
benign nevi and melanomas (Davies
et al., 2002). It has been implicated as a
critical mediator of melanoma devel-
opment, with the V600E-activating mu-
tation representing the most commonly
mutated form of BRAF in nevi and
melanomas (Pollock et al., 2003).
Despite strong evidence implicating
BRAF kinase as a bona-fide oncogene
Abbreviations: EGFR, epidermal growth factor receptor; HPM, human primary melanocyte; MMP-1,
matrix metalloproteinase-1; siRNA, small interfering RNA
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BRAF Activates Melanocyte MMP-1
